BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rheumatoid Arthritis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Rheumatoid Arthritis\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05428488-96@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT05428488)
DESCRIPTION:Orencia (Abatacept)\, phase 3\, Rheumatoid Arthritis.\nStudy: E
 fficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis\nEstima
 ted primary completion: November 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05428488
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590090-3826@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06590090)
DESCRIPTION:Methotrexate\, phase 2\, Rheumatoid Arthritis.\nStudy: Natrunix
  in Combination With Methotrexate for Rheumatoid Arthritis Treatment\nEsti
 mated primary completion: 15 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06590090
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590090-6351@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Natrunix: Phase 2 readout est. (NCT06590090)
DESCRIPTION:Natrunix\, phase 2\, Rheumatoid Arthritis.\nStudy: Natrunix in 
 Combination With Methotrexate for Rheumatoid Arthritis Treatment\nEstimate
 d primary completion: 15 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/natrunix#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06590090
URL:https://assetmemo.bio/drug/natrunix#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972446-103@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06972446)
DESCRIPTION:lutikizumab\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study t
 o Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthr
 itis\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06972446
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972446-5949@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ravagalimab: Phase 2 readout est. (NCT06972446)
DESCRIPTION:Ravagalimab\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study t
 o Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthr
 itis\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ravagalimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06972446
URL:https://assetmemo.bio/drug/ravagalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04870203-98@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT04870203)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy
 : Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis\nEstimat
 ed primary completion: March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/baricitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04870203
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409103-3826@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Methotrexate: Phase 2 readout est. (NCT07409103)
DESCRIPTION:Methotrexate\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study 
 to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Ac
 tive Rheumatoid Arthritis in Patients With an Inadequate Response to Metho
 trexate and Tumor Necrosis Factor Inhibition (START SYNERGY)\nEstimated pr
 imary completion: 15 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07409103
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137598-20@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:afimkibart: Phase 2 readout est. (NCT07137598)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study to
  Assess the Efficacy and Safety of RO7790121 in Participants With Moderate
  to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot To
 lerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)\nE
 stimated primary completion: 17 April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07137598
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998628-3826@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Methotrexate: Phase 2 readout est. (NCT06998628)
DESCRIPTION:Methotrexate\, phase 2\, Rheumatoid Arthritis.\nStudy: Pentoxif
 ylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis\nEstimat
 ed primary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06998628
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684157-2560@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JAB-8263: Phase 2 readout est. (NCT07684157)
DESCRIPTION:JAB-8263\, phase 2\, Rheumatoid Arthritis.\nStudy: A Phase IIa 
 Study of JAB-8263 in Patients With Active Rheumatoid Arthritis\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/jab-8263#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07684157
URL:https://assetmemo.bio/drug/jab-8263#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754462-10825@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT06754462)
DESCRIPTION:Imeroprubart\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study 
 to Evaluate the Efficacy\, Safety\, and Tolerability of IMVT-1402 in Adult
  Participants With Active\, Difficult to Treat Rheumatoid Arthritis\nEstim
 ated primary completion: September 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/imeroprubart#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06754462
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895524-75@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20271019
DTEND;VALUE=DATE:20271020
SUMMARY:MK-8690: Phase 2 readout est. (NCT07895524)
DESCRIPTION:MK-8690\, phase 2\, Rheumatoid Arthritis.\nStudy: A Clinical Tr
 ial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)\nEs
 timated primary completion: 19 October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/mk-8690#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07895524
URL:https://assetmemo.bio/drug/mk-8690#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276581-6198@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:AZD1163: Phase 2 readout est. (NCT07276581)
DESCRIPTION:AZD1163\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study to In
 vestigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid A
 rthritis\nEstimated primary completion: 12 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/azd1163#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07276581
URL:https://assetmemo.bio/drug/azd1163#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796516-5453@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07796516)
DESCRIPTION:Telitacicept\, phase 2\, Rheumatoid Arthritis.\nStudy: Efficacy
  and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arth
 ritis\nEstimated primary completion: 30 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07796516
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07295847-3183@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT07295847)
DESCRIPTION:AZD0120\, phase 1/2\, Rheumatoid Arthritis.\nStudy: A Study of 
 AZD0120 in Autoimmune Diseases\nEstimated primary completion: 22 February 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07295847
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-8@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Humira (adalimumab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Humira (adalimumab)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/adalimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-9@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Remicade (infliximab)\, phase 3\, Rheumatoid Arthritis.\nStudy:
  Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEs
 timated primary completion: March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-10@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cimzia (certolizumab pegol): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Cimzia (certolizumab pegol)\, phase 3\, Rheumatoid Arthritis.\n
 Study: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Respon
 se\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/certolizumab-pegol#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/certolizumab-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-15@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy:
  Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEs
 timated primary completion: March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-94@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enbrel (etanercept): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Enbrel (etanercept)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/etanercept#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-96@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Orencia (Abatacept): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Orencia (Abatacept)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/abatacept#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/abatacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-98@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy
 : Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nE
 stimated primary completion: March 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-3826@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methotrexate: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Methotrexate\, phase 3\, Rheumatoid Arthritis.\nStudy: Treatmen
 t of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstimated p
 rimary completion: March 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-4915@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-5478@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Hydroxychloroquine\, phase 3\, Rheumatoid Arthritis.\nStudy: Tr
 eatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-5897@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sarilumab: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Sarilumab\, phase 3\, Rheumatoid Arthritis.\nStudy: Treatment o
 f Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstimated prim
 ary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03414502
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5633@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Blinatumomab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704580-5897@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20281026
DTEND;VALUE=DATE:20281027
SUMMARY:Sarilumab: Phase 1/2 readout est. (NCT07704580)
DESCRIPTION:Sarilumab\, phase 1/2\, Rheumatoid Arthritis.\nStudy: Phase 1b/
 2 Study of IV Sarilumab in Adult With RA\nEstimated primary completion: 26
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarilu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07704580
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627893-3826@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Methotrexate: Phase 2/3 readout est. (NCT07627893)
DESCRIPTION:Methotrexate\, phase 2/3\, Rheumatoid Arthritis.\nStudy: Comple
 mentary Herbal Approach to Rheumatoid Management Study (CHARMS)\nEstimated
  primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/methotrexate#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07627893
URL:https://assetmemo.bio/drug/methotrexate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620392-20@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20330708
DTEND;VALUE=DATE:20330709
SUMMARY:afimkibart: Phase 2 readout est. (NCT07620392)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: An Extensi
 on Study to Assess Long-Term Safety and Efficacy of Afimkibart in Particip
 ants With Rheumatoid Arthritis\nEstimated primary completion: 8 July 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07620392
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
